Mirae Asset Global Investments Co., Ltd. Kymera Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,158 shares of KYMR stock, worth $76,198. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,158

Previous 2,336 7.62%

Holding current value

$76,198

Previous $110,000 21.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$39.06 - $51.84 $6,952 - $9,227	-178 Reduced 7.62%	2,158 $86,000
Q3 2024 Oct 23, 2024	BUY	$30.16 - $52.4 $15,200 - $26,409	504 Added 27.51%	2,336 $110,000
Q2 2024 Jul 30, 2024	SELL	$29.85 - $39.42 $675,774 - $892,429	-22,639 Reduced 92.51%	1,832 $54,000
Q1 2024 May 01, 2024	BUY	$22.9 - $43.57 $35,059 - $66,705	1,531 Added 6.67%	24,471 $983,000
Q4 2023 Jan 24, 2024	BUY	$10.97 - $26.84 $5,748 - $14,064	524 Added 2.34%	22,940 $584,000
Q3 2023 Oct 26, 2023	SELL	$13.9 - $23.88 $34,110 - $58,601	-2,454 Reduced 9.87%	22,416 $311,000
Q2 2023 Aug 10, 2023	SELL	$22.4 - $34.92 $15,635 - $24,374	-698 Reduced 2.73%	24,870 $571,000
Q1 2023 May 04, 2023	BUY	$24.84 - $38.75 $196,086 - $305,892	7,894 Added 44.66%	25,568 $757,000
Q4 2022 Feb 09, 2023	BUY	$19.57 - $30.92 $12,152 - $19,201	621 Added 3.64%	17,674 $441,000
Q3 2022 Nov 10, 2022	BUY	$20.91 - $34.27 $126,212 - $206,853	6,036 Added 54.79%	17,053 $371,000
Q2 2022 Jul 26, 2022	BUY	$14.13 - $42.55 $155,670 - $468,773	11,017 New	11,017 $217,000

Others Institutions Holding KYMR

# of Institutions

186

Shares Held

65.5M

Call Options Held

49.6K

Put Options Held

17K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.93B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Kymera Therapeutics, Inc. Transaction History